Traynor Capital Management, Inc. Kazia Therapeutics LTD Transaction History
Traynor Capital Management, Inc.
- $1.47 Billion
- Q4 2024
Shares
1 transactions
Others Institutions Holding KZIA
# of Institutions
17Shares Held
2.09MCall Options Held
93.2KPut Options Held
0-
Mai Capital Management1.36MShares$2 Million0.01% of portfolio
-
Ubs Group Ag249KShares$366,6940.0% of portfolio
-
Morgan Stanley New York, NY220KShares$323,7830.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il60.5KShares$88,8990.0% of portfolio
-
Jane Street Group, LLC New York, NY46.1KShares$67,7810.0% of portfolio
About KAZIA THERAPEUTICS LTD
- Ticker KZIA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,111,300
- Market Cap $22.2M
- Description
- Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various...